Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Author:

Stein Eytan M.12,DiNardo Courtney D.3,Pollyea Daniel A.4,Fathi Amir T.56,Roboz Gail J.27,Altman Jessica K.8,Stone Richard M.9,DeAngelo Daniel J.9,Levine Ross L.1,Flinn Ian W.10,Kantarjian Hagop M.3,Collins Robert11,Patel Manish R.12,Frankel Arthur E.11,Stein Anthony13,Sekeres Mikkael A.14,Swords Ronan T.15,Medeiros Bruno C.16,Willekens Christophe1718,Vyas Paresh1920,Tosolini Alessandra21,Xu Qiang21,Knight Robert D.21,Yen Katharine E.22,Agresta Sam22,de Botton Stephane1718,Tallman Martin S.12

Affiliation:

1. Memorial Sloan Kettering Cancer Center, New York, NY;

2. Weill Cornell Medical College, New York, NY;

3. The University of Texas MD Anderson Cancer Center, Houston, TX;

4. Division of Hematology, University of Colorado School of Medicine, Aurora, CO;

5. Massachusetts General Hospital Cancer Center, Boston, MA;

6. Department of Medicine, Harvard Medical School, Boston, MA;

7. New York Presbyterian Hospital, New York, NY;

8. Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL;

9. Dana-Farber Cancer Institute, Boston, MA;

10. Sarah Cannon Research Institute, Nashville, TN;

11. University of Texas Southwestern Medical Center, Dallas, TX;

12. Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL;

13. City of Hope Comprehensive Cancer Center, Duarte, CA;

14. Cleveland Clinic Taussig Cancer Institute, Cleveland, OH;

15. Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL;

16. Stanford Comprehensive Cancer Center, Stanford University, Stanford, CA;

17. Département d’Hématologie et Département d’Innovation Thérapeutique, Gustave Roussy, Villejuif, France;

18. University Paris Sud and Université Paris-Saclay, Le Kremlin-Bicêtre, France;

19. Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom;

20. National Institute for Health Research Oxford Biomedical Research Center, Oxford University Hospital, Oxford, United Kingdom;

21. Celgene Corporation, Summit, NJ; and

22. Agios Pharmaceuticals, Inc., Cambridge, MA

Abstract

Key Points Enasidenib, a selective inhibitor of mutant IDH2 enzymes, was safe and well tolerated in patients with IDH2-mutated myeloid malignancies. Enasidenib induced hematologic responses in patients with relapsed/refractory AML in this dose-escalation and expansion study.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3